Publication
WHS Law Briefing
Welcome to our WHS Law Briefing. This briefing identifies key issues and emerging trends in WHS Law, and details significant legislative and case law developments from August 2024 to date in February 2025.
Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies
The Life Sciences Lawyer Magazine
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Partner-in-Charge, San Francisco
Email
jason.novak@nortonrosefulbright.com
Recent publications
Publication
Pro bono Year in Review 2024
At Norton Rose Fulbright in Australia, pro bono is part of our firm’s cultural make-up and our social licence to operate.
Publication
The Australian Psychosocial Risk Perspective on Gender Diversity
It is critical that Australian business leaders consider the psychosocial risk perspective on gender diversity and ensure that their decision-making on this issue aligns with their obligations under work health and safety laws.
Subscribe and stay up to date with the latest legal news, information and events . . .